

Capital Markets
Deals
Review

H1 2021

Contents...

03 Foreword

04 Markets stats

05 Our Capital Markets transactions
H1 2021

06 Deals review

23 About PKF

24 Our Capital Markets credentials

25 How we can help

26 Our team

Our Capital Markets Deals Review H1 2021

The London Stock Exchange had a positive start to 2021, largely attributed to the success of the UK's vaccination programme and the promise of a return to "normality" from the UK Government.

Capital raising via IPOs broke a long-held record, with 49 IPOs completed in the first six months of 2021. Although the LSE welcomed issuers from the US, Canada, Israel, Russia, Australia and the EU, London continues to be Europe's most active exchange by a considerable margin, raising over £27bn in equity capital in the first half of 2021. It raised 55% more equity capital than its nearest European rival and is one of the world's four most active exchanges.

AIM continued to be the world's leading growth market and saw its highest level of daily trading in its 26-year history. In June, Victorian Plumbing became the largest-ever AIM IPO by market capitalisation (£850mn).

Although we have seen a number of successful transactions over the last year, we are now starting to see a far broader range of activity in a wider range of sectors, with companies looking to grasp opportunities quickly as the economy reopens. Main Market IPOs included Kanabo Group Plc, MGC Pharmaceuticals Limited and Cellular Goods Plc in February. MGC, leading the

way for medicinal cannabis companies on the LSE, raised £6.5m. MGC was shortly followed by Kanobo Group's reverse takeover in the cannabis space, raising £6m before expenses. PKF were delighted to act as reporting accountant for all three aforementioned cannabis transactions, which brought the total number of cannabis companies on LSE and AIM to six.

While the North American market is still more advanced compared to the UK, cannabis listings have taken off in the first quarter of 2021. The market is still relatively new, following UK legalisation of medical cannabis in 2018 and subsequently the FCA's announcement to allow medicinal cannabis companies to list on the LSE from September 2020.

We expect to see this trend continue and many more to come to market over the course of this year. We look forward to continuing to help our clients achieve their aspirations.



Mark Ling
Head of Capital Markets

📞 +44 (0)20 7516 2208
✉️ mling@pkf-l.com



Joseph Baulf
Capital Markets

📞 +44 (0)20 7516 2216
✉️ jbaulf@pkf-l.com



Dominic Roberts
Partner

📞 +44 (0)20 7516 2219
✉️ droberts@pkf-l.com



Adam Humphreys
Partner

📞 +44 (0)20 7516 2393
✉️ ahumphreys@pkf-l.com

Market stats

As of 30 June 2021

Main

Equity Market Value:

£3,786 billion

Number of companies:

1,126 companies

International listed companies:

211

UK Listed companies:

915

New money raised in 2021:

£3,159 million

AIM

Equity Market Value:

£147,074 billion

International listed companies:

112

UK listed companies:

714

New money raised in 2021:

£409 million

Raised from further issues:

£3,547 million

Aquis Growth Market

New companies admitted in 2021 to the AQSE Growth Market:

4

Companies listed on the Aquis Growth Market:

88

NASDAQ

New companies admitted in 2021:

H1 in 2021: 410



Companies listed on Nasdaq:

3,000+ companies

Market Capitalisation:

€19 trillion+

Our clients split across the markets



PKF Capital Markets transactions H1 2021

 Company	 Transaction date	 Market	 Transaction Type	 Sector	 Country of operations
Nightcap plc	January	AIM	Admission to AIM	Food & Beverage	UK
Equatorial Palm Oil plc	January	AIM	Re-admission to AIM and reverse takeover	Natural Resources	UK
MGC Pharmaceuticals Ltd	February	Main Market	Admission to the Main Market	Agribusiness & Soft Commodities	Australia, Europe
Kanabo Group Plc (formerly Spinnaker Opportunities plc)	February	Main Market	Re-admission to AIM and reverse takeover	Agribusiness & Soft Commodities	Europe, Israel
Path Investments plc	March	Main Market	Re-admission to the Main Market	Natural Resources	UK
Cellular Goods plc	March	Main Market	Admission to the Main Market	Agribusiness & Soft Commodities	UK
CYBA plc	March	Main Market	Admission to the Main Market	Technology	UK
Caerus Mineral Resources plc	March	Main Market	Admission to the Main Market	Natural Resources	Cyprus
Dev Clever Holdings plc	May	AIM	Re-admission to AIM	Technology	UK
East Star Resources plc	May	Main Market	Admission to the Main Market	Natural Resources	UK
Emmerson plc	May	AIM	Admission to AIM	Natural Resources	Morocco
Bould Opportunities plc	May	Main Market	Admission to the Main Market	Health & Wellness	UK
TECC Capital Plc	May	AQSE Growth Market	Admission to the AQSE Growth Market	Technology	UK
Pharma C Investments Plc	May	AQSE Growth Market	Admission to the AQSE Growth Market	Agribusiness & Soft Commodities	UK
Boanerges Limited	May	AQSE Growth Market	Admission to the AQSE Growth Market	Technology	UK
Thor Explorations	June	AIM	Admission to AIM	Natural Resources	Africa
Voyager Life Plc	June	AQSE Growth Market	Admission to the AQSE Growth Market	Agribusiness & Soft Commodities	UK, USA

Deals Review

Nightcap plc

ADMISSION TO AIM

**£13.5 million**

Approximate market capitalisation

**55,378,837**

Number of ordinary shares in issue

**10 Pence**

per share

Nightcap plc was admitted to the AIM market of the London Stock Exchange in January. Upon Admission, Nightcap acquired the London Cocktail Club for an initial consideration of £5.7 million (subject to adjustment in accordance with the terms of the Acquisition Agreement). The initial consideration was satisfied by the issue of 55,378,837 new Nightcap ordinary shares and a cash payment of £162,116.

The London Cocktail Club is an award-winning independent operator of 10 individually themed cocktail bars in 9 London locations and 1 location in Bristol, targeting customers aged between 26 to 40 years old.

In conjunction with Admission, Nightcap raised gross proceeds of £4.0 million through a fundraising that was comprised of a placing and an offer through PrimaryBid, at an issue price of 10 pence per share. Upon Admission, the Company had a market capitalisation of approximately £13.5 million.

PKF acted as reporting accountant on the transaction and the Capital Markets team included Joseph Baulf, Mark Ling and Lauren Haslam.

“ We greatly appreciated the support provided by the Capital Markets team at PKF. The timetable was challenging and we needed an experienced Reporting Accountant with a professional and efficient approach. This listing marks an important step in the growth plan of Nightcap Plc and we value the support of PKF in achieving these aspirations.”

Toby Rolph

CFO

Nightcap plc

Deals Review

Equatorial Palm Oil plc

ADMISSION TO THE AQSE GROWTH MARKET



£13.5 million

Approximate market capitalisation



16,666,666

Number of ordinary shares in issue



12 Pence

per share

Equatorial Palm Oil plc (renamed Capital Metals plc) was admitted to the AIM market of the London Stock Exchange in January, following its reverse takeover of a 99% interest in BVI company, Capita20I Metals Limited. Alongside the acquisition and readmission, CML raised £2 million through an oversubscribed share placing with institutional and other investors.

Capital Metals Limited was incorporated in 2015 to acquire licences prospective for mineral sands in Sri Lanka (the Project). The Project has an established JORC resource of 17.2Mt, of which 84% is in the measured and indicated categories, with an average grade of 17.6% total heavy minerals (THM), making it one of the highest-grade deposits in the global peer group. Less than 5% of the Project area has been drilled to date and the JORC Resource is from surface to a depth of three metres. Exploration work has shown continuation beyond three metres and also returned grades in excess of 26% THM. CML expects to be able to upgrade the size of the resource in due course. Additional adjoining exploration licences are also under application.

Following completion of the acquisition and the placing, CML's shares were readmitted to trading on 13 January 2021, with the ticker 'AIM:CMET' and a market capitalisation on admission of £20.6 million

PKF acted as reporting accountant on the transaction and the Capital Markets team included Dominic Roberts, Adam Humphreys and Lauren Haslam.

“We are delighted to have supported the team at Equatorial Palm Oil with this transaction and look forward to supporting them as they continue to grow.”

Adam Humphreys


Partner

PKF Littlejohn

Deals Review

MGC Pharmaceuticals Ltd

ADMISSION TO THE MAIN MARKET



£6.978 million

Approximate market capitalisation



£6.5m

Placing raised



3 Pence

per share

MGC Pharmaceuticals Ltd was admitted to the Main Market of the London Stock Exchange in February, following a strongly supported £6.5 million share placing led by leading UK institutional fund managers, and supported by UK family office and professional high net worth investors.

MGC Pharma is a European based and Australian listed bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines. MGC Pharma was the first medicinal cannabis related company to be admitted to the main market of the London Stock Exchange through a standard listing.

PKF acted as reporting accountant on the transaction and the Capital Markets team included Dominic Roberts, Adam Humphreys and Lauren Haslam.

“ Listing on the LSE for us has been the culmination of over 24 months hard work, and a vital step in the next stage of growth for MGC Pharma. The support that PKF provided to us throughout the process was invaluable, and has enabled us to make our ambition a reality.”

Roby Zomer

Managing Director and CEO
MGC Pharmaceuticals Ltd

Deals Review

Kanabo Group Plc

ADMISSION TO THE MAIN MARKET



£23.4 million

Approximate market capitalisation



£4,545,454

Number of ordinary shares in issue



2.5 Pence

per share

Kanabo Group Plc (formerly Spinnaker Opportunities plc) was admitted to the standard segment of the London Stock Exchange in February, following its reverse takeover of Israel-based medical cannabis company, Kanabo Research Ltd.

Kanabo successfully completed an IPO of £6 million that was oversubscribed, giving it a market capitalisation of approximately £23.4 million on admission. Kanabo was the first cannabis company to list by way of RTO on the London Stock Exchange.

PKF acted as reporting accountant on the transaction and the Capital Markets team included Dominic Roberts and Joseph Baulf.

“ We greatly appreciated the support provided by the Capital Markets team at PKF. The RTO was a landmark in the sector and we needed an experienced Reporting Accountant with a professional approach. This listing marks an important step in the growth plan of Kanabo Group Plc and the cannabis market as a whole in the EU.”

Avihu Tamir

CEO

Kanabo Group Plc

Deals Review

Path Investments plc

RE-ADMISSION TO AIM AND REVERSE TAKEOVER

**£3.85 million**

Fundraise

**1,540,000,000**Number of ordinary shares
in issue**0.25 Pence**

per share

Path Investments plc was re-admitted to trading on the standard segment of the Main Market in March.

The Company issued 1,540,000,000 new Ordinary Shares at an issue price of 0.25 pence each in connection with the Fundraise.

Path Investments plc strategy is to seek to acquire energy and natural resources assets which are capable of both producing a near-term income as well as offering a development upside. The Company targets long-life assets with corresponding cash-flows and with limited execution risk.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Joseph Baulf.

“ Path Investments plc’s raise of £3.5m goes a long way to continue to support its intentions to invest in companies with long-life assets to generate shareholder growth. We look forward to supporting them as they identify possible investments in the future.”

Joseph Baulf

PKF Littlejohn

Deals Review

Cellular Goods plc

ADMISSION TO THE MAIN MARKET



£25 million

Approximate market capitalisation



260,000,000

Number of ordinary shares in issue



5 Pence

per share

Cellular Goods plc was admitted to the Main Market of the London Stock Exchange in March, after it raised gross proceeds of £13 million through a 13 times oversubscribed IPO.

A total of 260,000,000 ordinary shares (representing 51.5% of the Company's issued share capital on Admission) were issued at 5 pence each to institutional and retail investors, valuing Cellular Goods at a market capitalisation in excess of £25 million.

Cellular was the first pure-play biosynthetic cannabinoids consumer products company to list on the London Stock Exchange, providing the investor community with a unique opportunity to capitalise on what researchers and analysts project to be a rapidly expanding market.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Joseph Baulf and Lauren Haslam.

“ We wanted to work with an experienced specialist in both capital markets and the growing cannabinoid sector when we decided to move forward with the IPO process. We value the support PKF Littlejohn provided in meeting our aspirations for the IPO and the future. We are excited about the future for Cellular Goods and the launch of our premium biosynthetic cannabinoid products later this year.”

Simon Walters


CFO

Cellular Goods plc

Deals Review

CYBA plc

ADMISSION TO THE MAIN MARKET

**£7.9 million**

Approximate market capitalisation

**524,525,000**

Number of ordinary shares in issue

**1.5 Pence**

per share

CYBA plc were admitted to the Main Market of the London Stock Exchange in March. CYBA plc is a special purpose acquisition vehicle formed to acquire and then act as the holding company for various target businesses operating in the Cyber Security industry. PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Joseph Baulf and Joseph Archer.

“We look forward to the exciting journey that CYBA Plc has lined up and supporting them along the way. CYBA has set itself up to be a disruptor in the cyber security market with regards to its future acquisitions of Polyswarm and Narf.”

Joseph Baulf
PKF Littlejohn

Deals Review

Caerus Mineral Resources plc

ADMISSION TO THE MAIN MARKET



£2,250,000
Raised



1,500,000
Number of ordinary
shares in issue



10 Pence
per share

Caerus Mineral Resources plc was admitted to the Main Market of the London Stock Exchange in March.

Caerus completed a placing of 21,000,000 new Ordinary shares at 10p and further Subscription Agreements for an aggregate 1,500,000 new Ordinary Shares at 10p to raise a cumulative £2,250,000. At listing, the total number of shares was 22,500,000.

Caerus Mineral Resources is an Exploration and Resource Development Company operating in the Republic of Cyprus. The Company's ambition is to generate value for all stakeholders through the discovery, development and production of copper and gold mineral resources.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Adam Humphreys and Lauren Haslam.

“The PKF team proved an integral part of our successful listing. Their expertise and depth of knowledge in mining sector listings was invaluable and guidance was consistently useful. We look forward to working with the team as PKF takes on our routine financial reporting.”

Martyn Churchouse


Chief Executive Officer

Caerus Mineral Resources plc

Deals Review

Dev Clever Holdings plc

RE-ADMISSION TO AIM



£6 million
raised



30,000,000
Number of new shares
in issue



10 Pence
Per share

Dev Clever published a secondary prospectus in May, following which 30 million new ordinary shares were issued to each of Intrinsic Capital Jersey Limited (ICJL) and Situs Limited at a price of 10 pence per share, raising a total of £6 million gross.

The net proceeds of the fundraise are expected to enable Dev Clever to accelerate its growth and broaden and strengthen its market position in the fast-growing EdTech sector.

Dev Clever is a leading developer of online and immersive career guidance and development platforms and consumer engagement experiences. The company specialises in the use of lightweight integrations of cloud-based VR and gamification technologies to deliver rich customer engagement experiences across both the education and commercial sectors.

PKF acted as reporting accountant on the transaction and the Capital Markets team included Adam Humphreys and Lauren Haslam.

“ We are delighted to have supported Dev Clever with their subscription agreement. Dev Clever is a leading developer of online and immersive career guidance and we look forward to supporting their continued growth.”

Adam Humphreys

Partner
PKF Littlejohn

Deals Review

East Star Resources plc

ADMISSION TO THE MAIN MARKET



£10.2 million

Approximate market capitalisation



204,445,957

Number of ordinary shares in issue



5 Pence

per share

East Star Resources plc was admitted to the Main Market of the London Stock Exchange in May.

Following the publication of East Star's prospectus on 27 April 2021, a total of 69,540,164 ordinary shares were admitted to the standard segment of the London Stock Exchange and it began trading on 4 May 2021.

East Star Resources Plc is a Special Purpose Acquisition Company, formed to seek acquisitions in the natural resources sector.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Adam Humphreys and Lauren Haslam.

“For our admission to the Standard List, we were looking for an experienced Reporting Accountant to support and guide us through the admission process. PKF's highly experienced and efficient Capital Markets team was a significant contributor to the successful admission to the LSE and we would recommend them to any companies looking to admit to the Standard List in London.”

Anthony Eastman
Non-Executive Director
East Star Resources plc

Deals Review

Emmerson plc

ADMISSION TO AIM



£5.5 million
placing



823,244,481
Number of ordinary
shares in issue



£47 million
Approximate market
capitalisation

Emmerson plc was admitted to trade on the AIM market in May.

Emmerson had undertaken a placing to raise £5.5m in conjunction with the proposed admission of the Ordinary Shares to trading on AIM. The Placing completed on 26 February 2021, prior to Admission and ahead of the proposed cancellation of the Company's listing on the Official List and admission to trading on the Main Market.

Emmerson plc is a potash development company focused on the development of the Khemisset Potash Project in Northern Morocco.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Dominic Roberts, John Black and Matt Willets.

“We worked closely with the PKF Capital Markets team and were very happy with their work and support on our fund raise and move to AIM.”

Hayden Locke


Director

Emmerson plc

Deals Review

Bould Opportunities plc

RE-ADMISSION TO AIM AND REVERSE TAKEOVER



£2.2 million

Approximate market capitalisation



22,000,000

Number of ordinary shares in issue



10 Pence

per share

Bould Opportunities plc (to be renamed Cizzle Biotechnology Holdings Plc) was admitted to the Main Market of the London Stock Exchange in May.

The Company completed a placing of 22,000,000 new ordinary shares at 10p per share to raise gross proceeds of £2.2 million. The Board intends to apply a majority of the net proceeds of the Placing towards the development of the C1Z1B biomarker test through to CE marking and/or FDA 510(k) clearance.

Cizzle Biotechnology is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as C1Z1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.

Cizzle Biotechnology is a spin-out from the University of York and was initially funded by Yorkshire Cancer Research, White Rose Technology Seed Corn Fund, Finance Yorkshire Seedcorn LLP and Viking Members who, with management, invested in the project to support the development of a prototype blood test.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Joseph Baulf.

“We were very pleased with the Capital Markets team at PKF on our admission to the Main Market. We wanted to work with a reporting accountant with significant experience in Capital Markets. PKF’s expertise and proactive support were important factors in enabling us to complete the acquisition and admission.”

Nigel Lee

FD
Bould Opportunities plc

Deals Review

TECC Capital Plc

ADMISSION TO THE AQSE GROWTH MARKET



£1,250 million
raised



25,000,000
Number of ordinary
shares in issue



5 Pence
per share

TECC Capital was admitted to trade on the AQSE Growth Market in May.

The Company raised £1,250,000 before expenses through the issue of 25,000,000 Ordinary Shares to a range of investors. TECC will focus on investing in businesses which are developing and/or supporting the application of technology in innovative sectors, such as

- Artificial intelligence and machine learning
- Telematics
- Life sciences (including medicinal cannabis and cannabidiol (CBD) wellness)
- Cyber security
- eCommerce (including big data and the internet of things (IOT)).

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Dominic Roberts and Lauren Haslam.

“The team at PKF gave us unwavering support during our recent admission to the Aquis Stock Exchange. Their experience in the public markets was evident throughout the process and they were incredibly proactive in ensuring any potential issues were dealt with early, preventing them becoming obstacles further down the line. We look forward to working with PKF going forwards on our listed journey.”

John Taylor

CEO

TECC Capital Plc

Deals Review

Pharma C Investments Plc

ADMISSION TO THE AQSE GROWTH MARKET



£1 million
Fundraise



269,857,144
Number of ordinary
shares in issue



0.7 Pence
Per share

Pharma C Investments was admitted to trade on the AQSE Growth Market in May.

Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal markets with a particular focus on the UK, EU and Israel and will provide capital, strategic insights and operational support. Pharma C is run by cannabis entrepreneurs who understand the unique challenges of the legal cannabis industry and thus can provide invaluable support and expertise for growing companies.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Joseph Baulf.

“ We wanted to work with an experienced specialist in both capital markets and the growing cannabinoid sector when we decided to move forward with the IPO process. We value the professionalism and support PKF Littlejohn provided in meeting our aspirations for the Aquis listing and our development going forward.”

Chana Greenberg

CEO

Pharma C Investments Plc

Deals Review

Boanerges Limited

ADMISSION TO THE AQSE GROWTH MARKET



£1,030 million

Approximate market capitalisation



54,750,001

Number of ordinary shares in issue



2 Pence

per share

Boanerges Limited was admitted to trade on the AQSE Growth Market in May.

Boanerges Limited focuses on companies which are based in the UK or Europe where there are opportunities to acquire interests in undervalued or pre-commercialisation technologies, or current commercialisation technologies, which when applied, produce cost saving or revenue enhancement for customers. Technology company acquisitions may include those involved in Big Data, Machine Learning, Telematics and Internet of Things sectors.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Joseph Baulf.


“It was a pleasure to support Boanerges on its listing on Aquis as a cash shell. The AQSE offers the perfect environment for Boanerges to grow and acquire companies in the highly competitive technology sector.”

Joseph Baulf
PKF Littlejohn

Deals Review

Thor Explorations

ADMISSION TO TRADE ON THE AIM MARKET



£135 million

Approximate market capitalisation



623,070,509

Number of common shares in issue



21 Pence

Share price as of 30 June

Thor Explorations was admitted to trade on the AIM market in June, with a market capitalisation of c£135 million at admission. The listing is supplementary to the Company's listing on the TSX-V in Canada.

Thor Explorations Ltd. is a mining and mineral exploration company engaged in the acquisition, exploration and development of mineral properties located in Nigeria, Senegal and Burkina Faso. Thor Explorations holds a 100% interest in the Segilola Gold Project located in Osun State of Nigeria and has a 70% economic interest in the Douta Gold Project located in south-eastern Senegal.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Dominic Roberts and Adam Humphreys.

“As the company moves to offer wider access for investors in West Africa's gold deposits, it was a pleasure to support Thor Explorations with its admission to the AIM market. We wish them all the best in the future and look forward to being a part of it.”

Adam Humphreys

Partner
PKF Littlejohn

Deals Review

Voyager Life plc

ADMISSION TO THE AQSE GROWTH MARKET



£400,000
raised



9,252,920
Number of ordinary
shares in issue



58 Pence
per share

Voyager Life plc have been admitted to trading on the Access Segment of the AQSE Growth Market in June.

The Company raised £400,000 on admission, having raised a total of £2.5 million to date since incorporation in November 2020, and had a market cap (at the time of IPO) of approximately £5.4 million.

Voyager Life plc offers a range of health and wellness products containing CBD and hemp seed oil.

PKF acted as Reporting Accountant on the transaction and the Capital Markets team included Joseph Baulf, Joseph Archer and Tim Harris.

“ We were looking for an experienced Reporting Accountant to help us through the admission process to the AQSE Growth Market and we were very pleased with the support that PKF provided during the process.”

Nick Tulloch

CEO

Voyager Life Plc



About PKF

Simplifying complexity for our clients

PKF is one of the UK's largest and most successful accountancy brands.

We have a strong reputation with publicly listed companies, and understanding these highly regulated, technically complex businesses has become a specialism of ours. We focus on delivering consistent quality and making all our clients feel valued.

Our specialist capital markets team has vast experience working with companies listed, or looking to list, on a range of international markets including the London Stock Exchange Main Market (Premium and Standard), AIM, AQUIS, NASDAQ & OTC, ASX and TSX & TSX-V.

PKF in the UK...



Ranked 11th
in the UK




£150 million
annual fee income



2,025+ staff



6th ranked auditor
of listed companies
in the UK



Our Capital Markets credentials

Our auditor rankings from ARL



Total AIM listed clients



Total UK stock market clients



Basic materials sector



Energy sector



Financials and Real Estate sector



Technology sector



PKF UK in numbers



Capital Markets in numbers



PKF International in numbers

11th
Largest accountancy brand in the UK

120
Listed audit clients

14th
Largest global accounting network

32
Offices across the UK

£2.7bn
Value of transactions advised on in last 10 years

480
Offices in 150 countries

2,025+
Employees and 158 partners

100+
Transactions advised on in last 5 years

\$1bn+
In aggregate fee income

£150m
Fee income and growing rapidly

30+
International businesses brought to the UK in last 10 years

20,000+
Employees



How we can help

We can help support businesses at each stage of their lifecycle, from pre-initial public offering (IPO) advice, throughout the IPO as reporting accountants and by providing ongoing support as auditors or providing accounting and tax support to meet your businesses requirements.

Visit our website to find out more.

Pre-IPO



IPO



Specialist transactions



Valuations



Audit & assurance



Tax



Business advisory



Business outsourcing



Get in touch today to see how we can help...

Capital Markets Transactions team



Dominic Roberts
Partner

📞 +44 (0)20 7516 2219
✉️ droberts@pkf-l.com



Mark Ling
Partner

📞 +44 (0)20 7516 2208
✉️ mling@pkf-l.com



Joseph Baulf
Capital Markets

📞 +44 (0)20 7516 2216
✉️ jbaulf@pkf-l.com



Adam Humphreys
Partner

📞 +44 (0)20 7516 2393
✉️ ahumphreys@pkf-l.com

Other Capital Markets partners



Joseph Archer
Partner

📞 +44 (0)20 7516 2495
✉️ jarcher@pkf-l.com



Zahir Khaki
Partner

📞 +44 (0)20 7516 2394
✉️ zkhaki@pkf-l.com



Jonathan Bradley-Hoare
Partner

📞 +44 (0)20 7516 2203
✉️ jbradley-hoare@pkf-l.com



Dave Thompson
Partner

📞 +44 (0)20 7516 2293
✉️ dthompson@pkf-l.com



This document is prepared as a general guide. No responsibility for loss occasioned to any person acting or refraining from action as a result of any material in this publication can be accepted by the author or publisher.

PKF Littlejohn LLP, Chartered Accountants. A list of members' names is available at the above address. PKF Littlejohn LLP is a limited liability partnership registered in England and Wales No. OC342572.

Registered office as above.

PKF Littlejohn LLP is a member firm of the PKF International Limited family of legally independent firms and does not accept any responsibility or liability for the actions or inactions of any individual member or correspondent firm or firms.

PKF International Limited administers a network of legally independent firms which carry on separate business under the PKF Name.

PKF International Limited is not responsible for the acts or omissions of individual member firms of the network.

PKF Littlejohn LLP,
15 Westferry Circus,
Canary Wharf,
London E14 4HD

Tel: +44 (0)20 7516 2200
www.pkf-l.com